^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Published date:
    01/28/2020
    Excerpt:
    Recommendation 1.3. For patients with high PD-L1 expression (TPS ≥ 50%), non-SCC, and PS 0 to 1, clinicians may offer atezolizumab/carboplatin/paclitaxel/bevacizumab in the absence of contraindications to bevacizumab (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
    DOI:
    10.1200/JCO.19.03022